Abstract
Tuberculosis (TB) has scourged humankind for millennia, and latent infection affects nearly one-third of today’s world population. The emergence of multidrug-resistant (MDR)-TB is a major global threat and reflects treatment failure of drug-sensitive disease. MDR-TB management is a burden for patients and society; success rates are unacceptably low with prolonged treatment duration. Mycobacterium tuberculosis (Mtb) possesses the ability to transform into a dormant state in which it can persist in the face of antimicrobial treatment and host defense. This sub-population of persisters is largely responsible for lengthy and difficult treatment. Targeting persistent bacilli could eventually improve the treatment success rate (currently 50–65 %) and shorten duration of treatment. A subset of therapies in the pipeline, termed therapeutic vaccines, use the host immune response to attack Mtb. The historical occurrence of an exacerbated host response has resulted in a negative perception of therapeutic vaccines. Thus, a renewed concept of immunotherapy is needed. We review current perspectives of immunotherapy in MDR-TB based on the knowledge of TB immunology and briefly discuss the profiles of several therapeutic vaccine products.
Similar content being viewed by others
Tuberculosis (TB) has been a scourge to humankind for thousands of years. With the advent of effective chemotherapy and declining incidence rates in affluent societies, interest in the disease waned [1]. In 1994, however, drug-resistant TB emerged [2, 3], and the World Health Organization (WHO) declared TB a Global Emergency [4]. Reports from New York show that drug-resistant TB was readily transmitted in the early 1990s among hospitalized AIDS patients. In 2010 alone, nearly 9.2 million new cases of TB occurred and an estimated 1.4 million deaths were caused by it [5]. The spread of HIV/AIDS accelerated the TB epidemic in large parts of the world, as the risk of developing the disease is markedly increased in HIV-infected persons [6].
MDR-TB and XDR-TB
When susceptibility to the two most powerful anti-tuberculosis drugs, isoniazid (H) and rifampicin (R), is lost, short-course treatment is no longer an option. HR resistance is referred to as multidrug-resistant (MDR)-TB. When resistance developes to not only HR, but also to two major second-line TB drug classes, the condition is referred to as extensively drug-resistant (XDR)-TB. By 2010, the WHO estimated the global prevalence of MDR-TB to be around 650,000 among the world’s 12.0 million cases of TB and 58 countries around the world have reported at least one case of XDR-TB [7, 8]. Countries of the Former Soviet Union have been among the most severely affected by the MDR-TB epidemic. A representative survey conducted in 2010 in Minsk, Belarus, showed alarming levels of drug resistance with nearly one out of two tuberculous patients being affected by MDR-TB [9]. Surveillance data from South Africa indicate a high prevalence of drug-resistant TB in the region [10], with a hall-mark paper reporting an alarmingly high mortality rate in XDR-TB patients co-infected with HIV [11]. Recent data from China have raised even greater concern. In a nation-wide survey on drug-resistant TB, 5.7 % of culture-positive pulmonary treatment-naïve cases appeared to have MDR-TB [12]. An independent survey in China revealed that 12 % of TB cases in one particular province were MDR-TB [13]. China has the second highest TB incidence in the world with India having the highest [7]. The case of China underlines the fact that MDR-TB has become an important global health threat. Increasing mobility and cross-border travel demands radical changes in the approach to combat TB [14, 15]. Currently available treatment for MDR- and XDR-TB requires administration of longer treatment with less effective, more costly, and more toxic drugs in comparison with the standard 6-month short-course chemotherapy for drug-susceptible TB: Indeed, the current treatment for MDR-TB is a burden for patients as well as for society [16, 17]. Nevertheless, treatment success with MDR-TB is low compared with that of drug-sensitive TB [18–20]. The emergence of a type of TB resistant to all currently available first- and second-line drugs—totally drug-resistent (TDR)-TB or very extensively drug-resistent (XXDR)-TB—has been reported in the last few years [21–23]. In summary, the emergence of ever-increasing resistance represents a major challenge for TB management in the future.
Risk factors for MDR-TB
Inadvertent monotherapy in multi-bacillary TB has been considered the driving mechanism in the bacillary repopulation of lesions by drug-resistant mutants, leading to monodrug resistance. When this process is repeated with another drug, MDR-TB results [24]. Previously defaulted or retreated cases, prolonged treatment time (>180 days), delayed initiation of chemotherapy, and misconducted treatment have all been associated with the development of MDR-TB [13, 25]. All of these factors have been alluded to as mistakes made by patients, doctors, and pharmacists. An alternative explanation was proposed by the group of Tawanda Gumbo, suggesting the role of interindividual pharmacokinetic (PK) variability of a single drug in the regimen—particularly H or R—as a major contributing factor in the development of MDR-TB rather than inappropriate treatment [26]. This would imply that drug resistance cannot be prevented even by well-designed standardized directly observed treatment, and that in one way or another, PK variability should be taken into account as an essential component in treatment and control programs.
Pathogenesis and immunology of TB
Several reviews on pathogenesis and immunology of TB have recently been published [27–31]. For the purpose of this review, we have summarized the main findings. Following aerogenic transmission from an individual with active disease, infectious droplets of Mycobacterium tuberculosis (Mtb)—the bacilli causing TB—reach the alveolar spaces. During its residency in lung parenchyma, Mtb can be phagocytosed either by alveolar macrophages (AM), dendritic cells (DC), epithelial cells, or neutrophils. These phagocytes are able to recognize the molecular components of Mtb—referred to as pathogen-associated molecular patterns—through pattern recognition receptors (PRR) on their cell surfaces. Much work has been done to reveal the PRR involved in the recognition process, which includes several receptor families such as toll-like receptors, nucleotide oligomerization domain-like receptors, C-type lectins, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (also known as CD209 or DC-SIGN), and dectin-1. Among the phagocytes expressing PRR, AM play a major role. AM possess the capability to produce essential cytokines and also act as a reservoir for Mtb bacilli. Once phagocytosed by these AM, Mtb may resist bactericidal actions by inhibiting phagolysosome function. Typically, macrophages acidify their phagosomes to pH 5.2 and kill the bacteria by the production of antimicrobial peptides (i.e., cathelicidin), activating a vitamin-D-dependent pathway [32]. The release of nitric oxide (NO) also constitutes an important defense mechanism in mouse models, but evidence in human studies has been conflicting [33, 34]. Several different mechanisms have been hypothesized and identified in halting phagosome maturation. Reduced recruitment of vacuolar H-ATPases hampers the acidification process and thus enables Mtb to persist inside the phagosomal vacuole [35, 36]. While lysosome fusion is altered, the vacuoles still fuse with other early endosomal vesicles while acquiring some lysosomal molecules by the conventional synthetic pathway [37]. GTPases of the Rab protein family are involved in lysosome fusion. Normally, Rab 5 is replaced by Rab 7, but Rab 5 is retained in phagosomes that contain Mtb [37]. Lipid bodies (LB)—dynamic and functionally active lipid-rich organelles—are the sites for these GTPases, and they play a role in transporting Rab into and from the phagosome in order to procure phagosome maturation [38]. LB also supply neutral lipids to the phagosome which can be utilized as an energy source by Mtb during its residency inside AM [39, 40]. Calcium-binding calmodulin is involved in early endosome fusion and calmodulin inhibitors inhibit fusion [41]. Suppression of the actin-binding coronin I (TACO in humans), which associates with early phagosomes, results in defective phagosome fusion [42]. In summary, Mtb inhibits phagosome maturation by several different mechanisms, and the pathogen persists intracellularly while avoiding macrophage apoptosis. During its residency in macrophages, Mtb can either multiply and eventually kill the host cell or alternatively once the infected macrophage is activated, Mtb can be destroyed. A third possibility, a unique feature of Mtb and leprosy bacilli, is that they fall into a stage of dormancy with low to absent metabolic and replicative activity.
If macrophages become necrotic, the bacilli enter the extracellular space where they are phagocytosed by other macrophages. This cycle ends only after the cell-mediated immune response is elicited with interferon-gamma (IFN-γ) released by CD4+ Th1 lymphocytes [43]. Upon recognition of major histocompatibility (MHC) class II molecules expressed by the infected macrophages, CD4+ T lymphocytes are able to polarize into distinct types of effector cells [44]. Th1 and Th17 T-lymphocytes play an important role in immunity to Mtb. Th1 lymphocytes produce several cytokines, including IFN-γ which is strongly associated with protective immunity. IFN-γ promotes macrophage activation by reviving phagosomal maturation, inducing NO-dependent apoptosis, and modulating autophagy thus enhancing Mtb clearance [45, 46]. IFN-γ as an immunogenic marker has been recommended by WHO as an assessment tool for new TB vaccine trials although it does not suffice as a marker of protection [47]. Th17 lymphocytes are involved in the early phase of host defense as they produce cytokines essential for neutrophil and monocyte recruitment to the site of infection. Th2 lymphocytes produce interleukin (IL)-4 that downregulates the Th1 response, thereby contributing to the development of progressive disease [48]. Treg lymphocytes produce transforming growth factor-beta (TGF-β) and IL-10, which inhibit all other CD4+ T cells. Apart from these CD4+ T lymphocytes, CD8+ T lymphocytes, which are MHC I-restricted, also contribute to protective immunity by directly lysing Mtb and producing Th1 type cytokines. Several innate immune cells, such as natural killer (NK) cells and gamma-delta (γδ) T cells, also play a role in the immune response against Mtb. As disease progresses, surface density of MHC class II molecules is decreased [49]. Costimulatory molecules are downregulated reducing cellular immune responses even further. Mtb also alters the cytokine profile around the macrophage. IL-6 attracts B-lymphocytes but reduces T-lymphocyte proliferation [49]. Hence, Mtb not only reduces the initiation of an effective host immune response, it also minimizes its effects.
The dormancy and persister stage of Mtb
Mtb and possibly leprosy bacilli have the unique capability to turn off their cellular metabolism, halt replication, and transform into a dormant stage under stress conditions (see Fig. 1) [50, 51]. While dormancy is typically induced by stress imposed by the host on Mtb, persistence refers to the survival of Mtb under harsh conditions, be they caused by drug treatment or host immunity. This makes it difficult for antituberculosis drugs to eliminate these organisms, which are therefore called “phenotypic persisters” or “phenotypic resistance” [52]. The sub-population of persistent Mtb organisms—though genetically identical to susceptible, fast-replicating, metabolically active bacteria—resist antimicrobial treatment and host immunity. At the same time, these dormant Mtb may not cause major harm to the host. This is the very reason why treatment is so lengthy and difficult [53]. Mtb enter the persister state expressing a range of different genes challenged by cellular immunity [54]. Through dormancy, the bacillus escapes the host immune response by many mechanisms [29, 53]. Dormant Mtb can persist in healthy individuals in a stage termed latent TB infection (LTBI).
Granulomas act as a suitable microenvironment where persisters of Mtb reside and persist [55], although earlier reports failed to show the presence of TB bacilli in lung granulomatous lesions [56]. Several other possible locations of these persistent Mtb, including adipose tissue, normal lung parenchyma, and several other organs, have been tentatively identified [57–59]. Tumor necrosis factor-alpha (TNF-α) plays a major role in granuloma formation and preservation [29], possibly with the involvement of other factors [60–62]. Granulomatous inflammation presents a complex cellular interplay to protect the host against invasion of organisms by walling Mtb off and attracting specific lymphocytes at the site of infection [63, 64]. An alternative hypothesis toward this assumption has however been proposed [65]. The Mtb region of difference-1 (RD-1) encoded ESX-1 secretion system enhances host expression of matrix metalloproteinase 9 (MMP-9), which is essential in initiating macrophage recruitment to the granuloma [66]. An increase in RD-1 expression by Mtb has been associated with an increased bacterial load [60]. If this is true, granuloma formation in its early stage—prior to T cells’ arrival—should be considered a pathogen-initiated response favoring the bacilli rather than a host defense mechanism.
The granuloma environment imposes several stress factors—such as low pH, NO, hypoxia, and limited nutrients—driving Mtb into dormancy. During this Mtb persister stage, stress-related genes are upregulated, while several central metabolism genes are downregulated [52]. The dormancy survival regulator (DosR)—transcription factors of Mtb responsible for increased expression of dormancy genes—upregulates the expression of several proteins crucial for Mtb survival under stress conditions. Some of these DosR regulon-encoded Mtb proteins evoke immunogenic responses when administered in a latently TB-infected individual [67]. Subsequent to phagocytosis, Mtb expresses DosR-encoded genes in the phagosome [68]. Transcriptome analysis from human smear-positive sputum samples revealed that Mtb persisters express signals of the DosR regulon [69]. IFN-γ production upon stimulation with some of these DosR regulon-encoded antigens may differentiate active and latent TB [70, 71]. Of the different stress factors, hypoxia is probably more critical than low pH, or increased NO and carbon monoxide production, in inducing activation of the DosR regulon [72, 73]. Disruption of DosR genes only slightly impairs the survival of Mtb in several animal models [52], suggesting that it might not be the only factor involved in the switch into dormancy. DosR is important for the initial hypoxic adaptation but not for the survival of Mtb during chemotherapy [74]. Genes encoded by sigma E transcription regulator are also involved in the stress response, and Mtb persistence inside macrophages [75].
Across a range of different stressor models studied, a set of five genes appear consistently upregulated. These genes are Rv0251c (acr2), encoding an α-crystallin heat shock protein (Hsp); Rv1152, a transcriptional regulator of the gntR family; Rv2497c (pdhA), encoding a possible pyruvate dehydrogenase component; Rv2517c, encoding a hypothetical protein; and Rv3290c (lat), encoding an l-lysine-epsilon-aminotransferase [74]. In a mouse model of Mtb infection, six other genes (fadE5, sigE, Rv2030c, Rv2660c, sigB, and ppsD) were consistently expressed—both during early and late stages of infection. One of these genes, Rv2660c—the most upregulated gene in an in vitro starvation model—encodes a hypothetical protein essential for adaptation to lack of nutrition and hypoxia [75]. A new multistage vaccine based on the Rv2660c antigen combined with two other early secreted antigens (Ag85B and early secreted antigenic target-6, or ESAT-6) appeared to prevent TB disease in a post-exposure TB infection model [76]. To what extent these persister genes are important in humans remains to be further elucidated, but their potential role in the switch of Mtb into dormancy may be important as a novel target for therapy.
Targeting persisters by drugs: old and new
Targeting the persister stage of Mtb may eventually lead to shorter drug regimens resulting in enhanced treatment success. Several old and new TB drugs are currently being tested for their activity against persistent bacteria, with the hope of shortening current regimens [53, 77]. Only a few new powerful drugs are in the pipeline [78], such as delamanid [79], bedaquiline [80], and the linezolid derivative sutezolid [81].
Animal models have been developed to assess elimination of persisters by using sterilization as an endpoint [82] but pharmacokinetics/pharmacodynamics (PK/PD) as well as the immune response in these animals is quite different from that of humans. Apart from novel therapeutic agents and novel therapeutic schedules, an important goal is to improve and optimize available second-line drugs by therapeutic drug monitoring and modeling [83–87]. Interindividual differences in PK/PD may be a more important driving force in the development of drug resistance than mistakes in medications [26, 88]. The strategy to optimize the use of current and novel drug therapy may however ultimately fail.
TB vaccines
Bacille Calmette–Guérin (BCG)—the only currently available TB vaccine—is a live attenuated strain of Mycobacterium bovis. It has been an important part of the Expanded Program on Immunization since the 1970s and has since been given more than 4 billion times. Its safety record is astonishing as few serious adverse events have been reported [89]. Yet, this 90-year-old vaccine does not protect against pulmonary TB in adults, its efficacy is minimal (0–80 %) in adults, and it provides only limited protection in children [90]. BCG remains controversial, and different policies and practices can be seen across nations [91]. Moreover, the current HIV epidemic places immune-compromised patients, who are being BCG vaccinated, at risk of developing BCG disease [92]. Promising progress can be seen in new TB vaccine development as many candidates have entered first clinical safety and immunogenicity evaluation. Eleven candidates have passed phase I clinical trials [93, 94]. Even more products are in the pipeline of preclinical development. Although these candidate vaccines represent potential improvements compared with BCG [95–97], they have not been shown to provide sterilizing immunity in a mouse model [98], and their potential value as therapeutic vaccines has not been assessed [99].
Therapeutic TB vaccine
Early initiation of anti-retroviral therapy provides benefit in preventing TB in HIV-infected individuals, highlighting the importance of enhanced cellular immunity to control LTBI [100]. Few vaccines use the host immune response to target active TB; these are termed therapeutic vaccines, though this is a misnomer. Two inactivated or fragmented mycobacterial formulations are considered for TB immunotherapy. Heat-killed Mycobacterium vaccae is an inactivated environmental mycobacterium. In phase III clinical trials, it was shown to be safe in HIV patients who had previously received BCG [92, 101]. M. vaccae immunotherapy enhances host defense against Mtb by promoting Th1 and suppressing Th2 response. When added to chemotherapy, M. vaccae improves sputum conversion and chest radiographic resolution [102, 103]. RUTI is composed of detoxified fragments representing a whole range of inactivated latency-associated antigens. In phase I clinical trials, its safety and immunogenicity has been demonstrated [104]. A phase II study for RUTI was recently completed, and a phase III trial is envisaged. Both are by far the most advanced therapeutic vaccines today. M. smegmatis and M. indicus pranii (MIP) are other saprophytic non-TB mycobacteria (NTM) that also share antigens with Mtb, similar with M. vaccae [105]. V-5 immunitor (V5)—an oral therapeutic vaccine initially developed for management of chronic hepatitis—has been shown in several studies to be beneficial when administered to TB patients [106, 107]. The authors suggest it could contain latency-associated Mtb antigen, resembling RUTI.
Current concept of immunotherapy
The use of therapeutic vaccines in TB was first suggested by Robert Koch in 1890. He believed that the use of repeated injections of supernatants of Mtb cultures—known as old tuberculin—could act as a potential remedy for TB [108]. In the absence of available treatment for TB, his ideas attracted many physicians around the world, and soon the old tuberculin was widely used. Tuberculin immunotherapy failed—in some instances it probably killed patients as a result of an exacerbated immune response [109]. With today’s knowledge, it is likely that administration of these antigens to already infected individuals resulted in a cytokine storm, a tissue-damaging, harmful response involving exacerbated release of TNF-α, as well as more down-stream pro-inflammatory cytokines [110]. Yet, no well conducted study has addressed the question whether, and under which circumstances, the old Tuberculin lacked safety.
The introduction of chemotherapy proved highly successful, especially after combination therapy was introduced [111]. With the emergence of drug-resistant TB, effectiveness of chemotherapy was challenged, and immunotherapy has been revisited [112]. To overcome the argument presented by this exacerbated immune response against the use of therapeutic vaccines, a modified concept is needed before they can be reconsidered.
There are two areas in which immunotherapy need to be applied. One, exemplified by M. vaccae, is that of immuno-modulation, in which the Th2 milieu induced and maintained by active tuberculous infection is corrected toward Th1, increasing the efficacy of chemotherapy. The other is elimination of persisters after a course of chemotherapy or in cases of latent tuberculosis that have never had clinical disease, for which the RUTI vaccine may be most effective.
Immune modulation needs to be applied as soon as diagnosis is confirmed, and chemotherapy started to correct the immune response away from that responsible for the pathology. The mechanism for this does not require antigens specific to Mtb, but reversion to Th1 restores cellular immune responses to antigens common to all mycobacteria, some of which are shared with human stress proteins expressed in tissues involved in chronic inflammation [113]. It is through this correction that immunotherapy with M. vaccae and some organisms related to it, results in its applicability to a range of chronic inflammatory diseases, many of them not mycobacterial in their etiology [114–121].
Eradication of persistent Mtb, which is virtually resistant to chemotherapy (see Fig. 2), is a modern concept. By reducing bacterial load, the cytokine storm which causes the Th2-related exacerbated immune response can be prevented [122]; this is essential for therapeutic vaccination. Indeed for this purpose, the focus should be on therapeutic vaccines that express latency-associated antigens as found in dormant Mtb. Such vaccination should assist the host immune system in boosting the immune response directed at these latency antigens, eventually resulting in complete eradication of persisting Mtb. They could be used to enhance the immune response during the continuation phase of TB treatment, in which the remaining bacteria are poorly sensitive, if not refractory, to antimycobacterial agents, and potentiate chemotherapy.
The greatest benefits for both types of immunotherapy would be for MDR-TB or XDR-TB as it would potentially improve the relatively low treatment success rate. Therapeutic vaccines do not interfere directly with the causative organism, and hence, they are not involved in the development of drug resistance [123]. Therapeutic vaccination would also be beneficial for drug-sensitive TB as it could potentially shorten the current 6-month standard therapy and help diminish the development of drug resistance. Finally, success in MDR-TB treatment could pave the way for a latency-targeted (post-exposure) vaccine. Indeed, reducing the huge reservoir of Mtb—drug-susceptible or not—by vaccination strategies could ultimately accelerate elimination of the disease.
Chemotherapy combined with immunotherapy should be the frontline approach in the management of MDR-TB. Early bactericidal activity of currently available second-line regimens is essential for the elimination of most replicating metabolically active Mtb bacilli in the early phase of treatment.
After significant reduction of the initial bacterial load with chemotherapy and M. vaccae, therapeutic vaccine(s) such as RUTI should be introduced in order to overcome the remaining persistent Mtb with slow replication rate and reduced drug sensitivity. The timing of immunotherapy initiation with RUTI is critical to prevent the emergence of an exacerbated immune response; chemotherapy, with or without M. vaccae, must have significantly reduced the bacterial load in advance.
Clinical, radiological, and bacteriological outcome, for example, using the vital stain fluorescent diacetate [124, 125], must be assessed in order to monitor true reduction in bacterial burden. In vitro susceptibility, fast molecular assays, and PK, using limited sampling of dried blood spots, should be incorporated to enhance the chance of drug treatment success. Eventually, additional modalities, such as nutritional intervention and surgical resection, should also be considered during the course of treatment.
Outlook
The classical approach using combined drug regimens remains the key modality in MDR-TB management. Additional support, such as nutritional intervention (by micronutrients and macronutrients) [126–128], and in selected cases, surgical resection [129, 130] are also important for beneficial outcome. However, considering the current low rate of success as well as the long duration of therapy in MDR-TB treatment, immunotherapy should now be explored in a formal randomized fashion. Current understanding of immune responses against Mtb should lead the way to further developing the concept of immunotherapy. The immunogenicity and safety of two therapeutic TB vaccines, M. vaccae and RUTI, have been demonstrated in preclinical work and in human trials. M. vaccae evokes optimal therapeutic results when given in multiple doses, while RUTI should probably best be given after significant reduction of bacterial load. For the RUTI product, further safety studies are necessary to reduce the risk of a pathologic immune response. M. vaccae restores Th1/Th2 balance, while RUTI exposes the host with specific sets of inactivated latency or dormancy antigens. Hence, administration of both vaccines in combination might be worth pursuing. Indeed, immunotherapy is now ready for prime time.
References
Keshavjee S, Farmer PE (2012) Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med 367(10):931–936
Frieden TR, Sterling T, Pablos-Mendez A, Kilburn JO, Cauthen GM, Dooley SW (1993) The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328(8):521–526
Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM, Ong KR, Kilburn JO, Dooley SW, Castro KG (1992) An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 326(23):1514–1521
World Health Organization (1994) Tuberculosis: a global emergency. WHO, Geneva
Raviglione M, Marais B, Floyd K et al (2012) Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet 379(9829):1902–1913
Swaminathan S, Ramachandran R, Baskaran G, Paramasivan CN, Ramanathan U, Venkatesan P, Prabhakar R, Datta M (2000) Risk of development of tuberculosis in HIV-infected patients. Int J Tuberc Lung Dis 4(9):839–844
World Health Organization (2011) Global tuberculosis control. WHO, Geneva
Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lönnroth K, Weil D, Raviglione M (2010) MDR tuberculosis—critical steps for prevention and control. N Engl J Med 363(11):1050–1058
Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, van Gemert W, Hoffner S, Rusovich V, Zignol M (2012) Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 39(6):1425–1431
World Health Organization (2010) Multidrug and extensively drug-resistant TB (M/XDR TB)—Global Report on Surveillance and Response 2010. WHO, Geneva
Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368(9547):1575–1580
Zhao Y, Xu S, Wang L et al (2012) National survey of drug-resistant tuberculosis in China. N Engl J Med 366(23):2161–2170
Liang L, Wu Q, Gao L et al (2012) Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax 67(7):632–638
Olson EN (2004) Undermining the endothelium by ablation of MAPK-MEF2 signaling. J Clin Invest 113(8):1110–1112
Chaisson RE, Nuermberger EL (2012) Confronting multidrug-resistant tuberculosis. N Engl J Med 366(23):2223–2224
Ahuja SD, Ashkin D, Avendano M et al (2012) Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 9(8):e1001300
Diel R, Rutz S, Castell S, Schaberg T (2012) Cost of illness of tuberculosis in Germany. Eur Respir J 40(1):143–151
Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP (2009) Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 9(3):153–161
Yew WW, Lange C, Leung CC (2011) Treatment of tuberculosis: update 2010. Eur Respir J 37(2):441–462
Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, Chen MP, Skenders G, Holtz TH (2010) Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000–2004. Eur Respir J 36(3):584–593
Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM (2007) First tuberculosis cases in Italy resistant to all tested drugs. Euro Surveill Eur Commun Dis Bull 12(5):E070517.1
Velayati AA, Masjedi MR, Farnia P, Tabarsi P, Ghanavi J, ZiaZarifi AH, Hoffner SE (2009) Emergence of new forms of totally drug-resistant Tuberculosis Bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 136(2):420–425
Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C (2012) Totally drug-resistant tuberculosis in India. Clin Infect Dis 54(4):579–581
Chang KC, Leung CC, Grosset J, Yew WW (2011) Treatment of tuberculosis and optimal dosing schedules. Thorax 66(11):997–1007
Faustini A (2006) Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax 61(2):158–163
Pasipanodya JG, Srivastava S, Gumbo T (2012) Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy. Clin Infect Dis 55(2):169–177
Axelsson-Robertson R, Magalhaes I, Parida SK, Zumla A, Maeurer M (2012) The Immunological footprint of Mycobacterium tuberculosis T-cell epitope recognition. J Infect Dis 205(suppl 2):S301–S315
Gupta A, Kaul A, Tsolaki AG, Kishore U, Bhakta S (2012) Mycobacterium tuberculosis: immune evasion, latency and reactivation. Immunobiology 217(3):363–374
van Altena R, Duggirala S, Gröschel MIP, van der Werf TS (2011) Immunology in tuberculosis: challenges in monitoring of disease activity and identifying correlates of protection. Curr Pharm Des 17(27):2853–2862
Kleinnijenhuis J, Oosting M, Joosten LAB, Netea MG, van Crevel R (2011) Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol 2011:1–12
Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y (2010) The immunology of tuberculosis: from bench to bedside. Respirology 15(3):433–450
Fabri M, Stenger S, Shin D-M et al (2011) Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med 3(104):104ra102
Schaible UE, Sturgill-Koszycki S, Schlesinger PH, Russell DG (1998) Cytokine activation leads to acidification and increases maturation of Mycobacterium avium-containing phagosomes in murine macrophages. J Immunol 160(3):1290–1296
Liu PT, Modlin RL (2008) Human macrophage host defense against Mycobacterium tuberculosis. Curr Opin Immunol 20(4):371–376
Welin A, Lerm M (2012) Inside or outside the phagosome? The controversy of the intracellular localization of Mycobacterium tuberculosis. Tuberc (Edinb) 92(2):113–120
Rohde KH, Abramovitch RB, Russell DG (2007) Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues. Cell Host Microbe 2(5):352–364
Russell DG (2001) Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2(8):569–577
Melo RCN, Dvorak AM (2012) Lipid body–phagosome interaction in macrophages during infectious diseases: host defense or pathogen survival strategy? PLoS Pathog 8(7):e1002729
Peyron P, Vaubourgeix J, Poquet Y et al (2008) Foamy macrophages from tuberculous patients’ granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog 4(11):e1000204
Pandey AK, Sassetti CM (2008) Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci USA 105(11):4376–4380
Colombo MI, Beron W, Stahl PD (1997) Calmodulin regulates endosome fusion. J Biol Chem 272(12):7707–7712
Maniak M, Rauchenberger R, Albrecht R, Murphy J, Gerisch G (1995) Coronin involved in phagocytosis: dynamics of particle-induced relocalization visualized by a green fluorescent protein Tag. Cell 83(6):915–924
Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178(6):2249–2254
Kaufmann SHE (2010) Novel tuberculosis vaccination strategies based on understanding the immune response. J Int Med 267(4):337–353
Herbst S, Schaible UE, Schneider BE (2011) Interferon gamma activated macrophages kill mycobacteria by nitric oxide induced apoptosis. PLoS ONE 6(5):e19105
Ní Cheallaigh C, Keane J, Lavelle EC, Hope JC, Harris J (2011) Autophagy in the immune response to tuberculosis: clinical perspectives. Clin Exp Immunol 164(3):291–300
Hanekom WA, Dockrell HM, Ottenhoff THM, Doherty TM, Fletcher H, McShane H, Weichold FF, Hoft DF, Parida SK, Fruth UJ (2008) Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med 5(7):e145
Rook GAW, Hernández-Pando R, Dheda K, Teng Seah G (2004) IL-4 in tuberculosis: implications for vaccine design. Trends Immunol 25(9):483–488
VanHeyningen TK, Collins HL, Russell DG (2001) IL-6 produced by macrophages infected with Mycobacterium species suppresses T cell responses. J Immunol 158(1):330–337
Hett EC, Rubin EJ (2008) Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev 72(1):126–156
Cardona P-J (2006) RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberc (Edinb) 86(3–4):273–289
Gengenbacher M, Kaufmann SHE (2012) Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev 36(3):514–532
Zhang Y, Yew WW, Barer MR (2012) Targeting persisters for tuberculosis control. Antimicrob Agents Chemother 56(5):2223–2230
Cardona P-J (2010) Revisiting the natural history of tuberculosis. Arch Immunol Ther Exp (Warsz) 58(1):7–14
Barry CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D (2009) The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7(12):845–855
Locht C, Rouanet C, Hougardy J-M, Mascart F (2007) How a different look at latency can help to develop novel diagnostics and vaccines against tuberculosis. Expert Opin Biol Ther 7(11):1665–1677
Neyrolles O, Hernández-Pando R, Pietri-Rouxel F et al (2006) Is adipose tissue a place for Mycobacterium tuberculosis persistence? PLoS ONE 1(1):e43
Hernandez-Pando R, Jeyanathan M, Mengistu G, Aguilar D, Orozco H, Harboe M, Rook GA, Bjune G (2000) Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 356(9248):2133–2138
Barrios-Payan J, Saqui-Salces M, Jeyanathan M, Alcantara-Vazquez A, Castanon-Arreola M, Rook G, Hernandez-Pando R (2012) Extrapulmonary locations of Mycobacterium tuberculosis DNA during latent infection. J Infect Dis 206(8):1194–1205
Clay H, Volkman HE, Ramakrishnan L (2008) Tumor necrosis factor signaling mediates resistance to mycobacteria by inhibiting bacterial growth and macrophage death. Immunity 29(2):283–294
Lin PL, Myers A, Smith L et al (2010) Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 62(2):340–350
Iliopoulos A, Psathakis K, Aslanidis S, Skagias L, Sfikakis PP (2006) Tuberculosis and granuloma formation in patients receiving anti-TNF therapy. Int J Tuberc Lung Dis 10(5):588–590
Bru A, Cardona P-J (2010) Mathematical modeling of tuberculosis bacillary counts and cellular populations in the organs of infected mice. PLoS ONE 5(9):e12985
Cardona P-J, Ivanyi J (2011) The secret trumps, impelling the pathogenicity of tubercle bacilli. Enferm Infecc Microbiol Clin 29(Suppl 1):14–19
Ramakrishnan L (2012) Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 12(5):352–366
Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L (2010) Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 327(5964):466–469
Black GF, Thiel BA, Ota MO et al (2009) Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol 16(8):1203–1212
Schnappinger D, Schoolnik GK, Ehrt S (2006) Expression profiling of host pathogen interactions: how Mycobacterium tuberculosis and the macrophage adapt to one another. Microb Infect 8(4):1132–1140
Garton NJ, Waddell SJ, Sherratt AL et al (2008) Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 5(4):e75
Chegou NN, Black GF, Loxton AG et al (2012) Potential of novel Mycobacterium tuberculosis infection phase-dependent antigens in the diagnosis of TB disease in a high burden setting. BMC Infect Dis 12(1):10
Chegou NN, Essone PN, Loxton AG et al (2012) Potential of host markers produced by infection phase-dependent antigen-stimulated cells for the diagnosis of tuberculosis in a highly endemic area. PLoS ONE 7(6):e38501
Boon C, Dick T (2010) How Mycobacterium tuberculosis goes to sleep: the dormancy survival regulator DosR a decade later. Futur Microbiol 7(4):513–518
Wayne LG, Sohaskey CD (2001) Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 55:139–163
Keren I, Minami S, Rubin E, Lewis K (2011) Characterization and transcriptome analysis of Mycobacterium tuberculosis persisters. mBio 2(3):e00100–e00111
Manganelli R, Voskuil MI, Schoolnik GK, Smith I (2001) The Mycobacterium tuberculosis ECF sigma factor sigmaE: role in global gene expression and survival in macrophages. Mol Microbiol 41(2):423–437
Aagaard C, Hoang T, Dietrich J, Cardona P-J, Izzo A, Dolganov G, Schoolnik GK, Cassidy JP, Billeskov R, Andersen P (2011) A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med 17(2):189–194
Mitchison D, Davies G (2012) The chemotherapy of tuberculosis: past, present and future [State of the art]. Int J Tuberc Lung Dis 16(6):724–732
Lienhardt C, Raviglione M, Spigelman M, Hafner R, Jaramillo E, Hoelscher M, Zumla A, Gheuens J (2012) New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 205(suppl 2):S241–S249
Gler MT, Skripconoka V, Sanchez-Garavito E et al (2012) Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 366(23):2151–2160
Diacon AH, Donald PR, Pym A et al (2012) Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 56(6):3271–3276
Alffenaar JWC, van der Laan T, Simons S, van der Werf TS, van de Kasteele PJ, de Neeling H, van Soolingen D (2011) Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob Agents Chemother 55(3):1287–1289
Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL (2012) Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 56(6):3114–3120
Pranger AD, Kosterink JGW, van Altena R, Aarnoutse RE, van der Werf TS, Uges DRA, Alffenaar J-WC (2011) Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis. Ther Drug Monit 33(3):350–354
Pranger AD, van Altena R, Aarnoutse RE, van Soolingen D, Uges DRA, Kosterink JGW, van der Werf TS, Alffenaar JWC (2011) Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 38(4):888–894
Alffenaar J-WC, van Altena R, Harmelink IM, Filguera P, Molenaar E, Wessels AMA, van Soolingen D, Kosterink JGW, Uges DRA, van der Werf TS (2010) Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients. Clin Pharmacokinet 49(8):559–565
Alffenaar J-WC, Kosterink JGW, van Altena R, van der Werf TS, Uges DRA, Proost JH (2010) Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis. Ther Drug Monit 32(1):97–101
Alffenaar JWC, van Altena R, Bökkerink HJ, Luijckx GJ, van Soolingen D, Aarnoutse RE, van der Werf TS (2009) Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis 49(7):1080–1082
Srivastava S, Pasipanodya JG, Gumbo T (2012) Reply to Alffenaar. J Infect Dis 205(11):1766
McShane H (2011) Tuberculosis vaccines: beyond bacille Calmette-Guerin. Philos Trans R Soc Lond B Biol Sci 366(1579):2782–2789
Kaufmann SH, Hussey G, Lambert P-H (2010) New vaccines for tuberculosis. Lancet 375(9731):2110–2119
Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M (2011) The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS Med 8(3):e1001012
Ottenhoff THM, Kaufmann SHE (2012) Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 8(5):e1002607–e1002612
Maleszewska M, Moonen J-RAJ, Huijkman N, van de Sluis B, Krenning G, Harmsen MC (2012) IL-1β and TGFβ2 synergistically induce endothelial to mesenchymal transition in an NFκB-dependent manner. Immunobiology. doi:10.1016/j.imbio.2012.05.026
Beresford B, Sadoff JC (2010) Update on research and development pipeline: tuberculosis vaccines. Clin Infect Dis 50(s3):S178–S183
Krenning G, Zeisberg EM, Kalluri R (2010) The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 225(3):631–637
Kaufmann SHE (2010) Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 33(4):567–577
World Health Organization (2011) Global Plan to Stop TB. WHO, Geneva
Skeiky YAW, Alderson MR, Ovendale PJ et al (2004) Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172(12):7618–7628
Grange JM, Brunet LR, Rieder HL (2011) Immune protection against tuberculosis—when is immunotherapy preferable to vaccination? Tuberc (Edinb) 91(2):179–185
Suthar AB, Lawn SD, del Amo J et al (2012) Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 9(7):e1001270
von Reyn CF, Mtei L, Arbeit RD et al (2010) Prevention of tuberculosis in Bacille Calmette–Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 24(5):675–685
Stanford JL, Grange JM (1994) The promise of immunotherapy for tuberculosis. Respir Med 88(1):3–7
Yang X-Y, Chen Q-F, Li Y-P, Wu S-M (2011) Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS ONE 6(9):e23826
Vilaplana C, Montané E, Pinto S, Barriocanal AM, Domenech G, Torres F, Cardona PJ, Costa J (2010) Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI®. Vaccine 28(4):1106–1116
Hawkridge T, Mahomed H (2011) Prospects for a new, safer and more effective TB vaccine. Paediatr Respir Rev 12(1):46–51
Arjanova VO, Prihoda DN, Yurchenko VL, Sokolenko NI, Frolov MV (2010) Phase 2 trial of V-5 Immunitor (V5) in patients with chronic hepatitis C Co-infected with HIV and Mycobacterium tuberculosis. J Vaccines Vaccin 01(01):1–5
Butov DA, Pashkov YN, Stepanenko AL, Choporova AI, Butova TS, Batdelger D, Jirathitikal V, Bourinbaiar AS, Zaitzeva SI (2011) Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB. J Immune Based Ther Vaccines 9(1):3
Koch R (1891) A further communication on a remedy for tuberculosis. BMJ 1(1568):125–127
Gradmann C (2001) Robert Koch and the pressures of scientific research: tuberculosis and tuberculin. Med Hist 45(1):1–32
Die Atiologie der Tuberculose. Facsimile of the original contribution by Robert Koch in “Berliner Klinische Wochenschrift” 10 April 1882
British Medical Research Council (1972) Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1(7760):1079–1085
Grange JM (1997) Immunotherapy: a new strategy for tuberculosis control? Respir Med 91(1):1–4
Stanford J, Stanford C, Stansby G, Bottasso O, Bahr G, Grange J (2009) The common mycobacterial antigens and their importance in the treatment of disease. Curr Pharm Des 15(11):1248–1260
Camporota L, Corkhill A, Long H et al (2003) The effects of Mycobacterium vaccae on allergen-induced airway responses in atopic asthma. Eur Respir J 21(2):287–293
Fontanella GH, Pascutti MF, Daurelio L, Perez AR, Nocito AL, Wojdyla D, Bottasso O, Revelli SS, Stanford JL (2007) Improved outcome of Trypanosoma cruzi infection in rats following treatment in early life with suspensions of heat-killed environmental Actinomycetales. Vaccine 25(17):3492–3500
Stansby G, Chan YC, Berwanger CS, Shurey S, Rook GAW, Stanford JL (2002) Prevention of experimental myointimal hyperplasia by immunomodulation. Eur J Vasc Endovasc Surg 23(1):23–28
Abbot NC, Beck JS, Feval F, Weiss F, Mobayen MH, Ghazi Saidi K, Dowlati Y, Velayati AA, Stanford JL (2002) Immunotherapy with Mycobacterium vaccae and peripheral blood flow in long-treated leprosy patients, a randomised, placebo-controlled trial. Eur J Vasc Endovasc Surg 24(3):202–208
Stanford JL, Stanford CA, O’Brien MER, Grange JM (2008) Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 44(2):224–227
Marro A, Pirles M, Schiaffino L, Bin L, Dávila H, Bottasso OA, McIntyre G, Ripley PR, Stanford CA, Stanford JL (2011) Successful immunotherapy of canine flea allergy with injected Actinomycetales preparations. Immunotherapy 3(8):971–978
Ramu G, Prema GD, Balakrishnan S, Shanker Narayan NP, Stanford JL (1990) A preliminary report on the immunotherapy of psoriasis. Indian Med Gazette 124:381–382
Lehrer A, Bressanelli A, Wachsmann V, Bottasso O, Bay ML, Singh M, Stanford C, Stanford J (1998) Immunotherapy with Mycobacterium vaccae in the treatment of psoriasis. FEMS Immunol Med Microbiol 21(1):71–77
Gil O, Guirado E, Gordillo S, Díaz J, Tapia G, Vilaplana C, Ariza A, Ausina V, Cardona P-J (2006) Intragranulomatous necrosis in lungs of mice infected by aerosol with Mycobacterium tuberculosis is related to bacterial load rather than to any one cytokine or T cell type. Microb Infect 8(3):628–636
Uhlin M, Andersson J, Zumla A, Maeurer M (2012) Adjunct immunotherapies for tuberculosis. J Infect Dis 205(suppl 2):S325–S334
Van Deun A, Maug AKJ, Hossain A, Gumusboga M, de Jong BC (2012) Fluorescein diacetate vital staining allows earlier diagnosis of rifampicin-resistant tuberculosis. Int J Tuberc Lung Dis 16(9):1174–1179
Hamid Salim A, Aung K, Hossain MA, Van Deun A (2006) Early and rapid microscopy-based diagnosis of true treatment failure and MDR-TB. Int J Tuberc Lung Dis 10(11):1248–1254
Warmelink I, ten Hacken NH, van der Werf TS, van Altena R (2010) Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity. Br J Nutr 105(03):400–408
Warmelink I, van Altena R, ten Hacken N, van der Werf T, van der Veer E (2011) Nutritional status and vitamin D3 during antimicrobial treatment. Lancet 377(9775):1407–1408
Campbell GR, Spector SA (2012) Vitamin D inhibits human immunodeficiency virus type 1 and Mycobacterium tuberculosis infection in macrophages through the induction of autophagy. PLoS Pathog 8(5):e1002689
Kempker RR, Vashakidze S, Solomonia N, Dzidzikashvili N, Blumberg HM (2012) Surgical treatment of drug-resistant tuberculosis. Lancet Infect Dis 12(2):157–166
Iddriss A, Padayatchi N, Reddy D, Reddi A (2012) Pulmonary resection for extensively drug resistant tuberculosis in Kwazulu-Natal, South Africa. Ann Thorac Surg 94(2):381–386
Author information
Authors and Affiliations
Corresponding author
Additional information
Satria A. Prabowo and Matthias I. Gröschel equally contributed to the work.
Rights and permissions
About this article
Cite this article
Prabowo, S.A., Gröschel, M.I., Schmidt, E.D.L. et al. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol 202, 95–104 (2013). https://doi.org/10.1007/s00430-012-0278-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00430-012-0278-6